

Cucurbit[7]uril Inhibits Islet Amyloid Polypeptide Aggregation by Targeting N Terminus Hot Segments and Attenuates Cytotoxicity



Debabrata Maity



Yujeong Oh




Lothar Gremer



Wolfgang Hoyer



Mazin Magzoub



Andrew D. Hamilton

Invited for the cover of this issue is the group of Prof. Hamilton at New York University. The image depicts how cucurbit[7]uril inhibits islet amyloid polypeptide self-assembly that rescues rat insulinoma cells (a pancreatic β -cell model) from assembly-associated cytotoxicity. Read the full text of the article at 10.1002/chem.202200456.

What is the most significant result of this study?

Islet amyloid polypeptide (IAPP) and amyloid-beta ($A\beta_{42}$) are two intrinsically disordered peptides, whose amyloid aggregation is implicated in type 2 diabetes and Alzheimer's disease, respectively. The two peptides share a high degree of sequence similarity in their major nucleation sites for amyloidogenesis. An earlier report showed that more than 500 equivalents of cucurbit[7]uril (CB[7]) are required for complete inhibition of $A\beta_{42}$ aggregation. Here, we have extended this approach toward IAPP aggregation. Our studies demonstrate that CB[7] is a much more potent disruptor of IAPP self-assembly, with only 10 equivalents of the macrocycle proving sufficient for complete inhibition of de novo and membrane-catalyzed IAPP aggregation, and the associated downstream toxic effects. Our work, therefore, outlines a potential supramolecular-based therapeutic strategy for type 2 diabetes.

Who designed the cover?

Khulood Alawadi, Lecturer in Engineering Design, New York University Abu Dhabi, designed the cover image with suggestions from D.M.

What prompted you to investigate this topic/problem?

Protein misfolding often leads to the formation of β -sheet-rich amyloid plaques, which are associated with the progression of a wide range of diseases. As IAPP is implicated in the development of type 2 diabetes, modulation of this peptide's aggregation is critical from a therapeutic point of view. Crucially, aggregation of these so-called amyloid proteins is primarily driven by hydrophobic interactions. Recently, different macrocycles have been used for selective encapsulation of hydrophobic amino acids. We, therefore, explored whether the CB[7] macrocycle can interact with hydrophobic amino acids in IAPP and effectively disrupt its amyloid aggregation.

How did each team member/collaborator contribute to the work?

D.M. and A.D.H. conceptualized the project. L.G. and W.H. synthesized the ^{15}N -IAPP. D.M. performed all biophysical studies and HSQC NMR. Y.O. and M.M. designed and performed all the cytotoxicity assays. D.M. and A.D.H. wrote the manuscript with contributions from all of the co-authors.

